I think it's all about a partnership and the anticipation of approval. If we have both by the time the data's revealed for 184 events, it's a possibility. As I see that, it's ASCO 2010, roughly the first week in June.
On the other hand, if the data's good, but still is subject to questions about approval at trial completion, it could be some time.
IMHO, unless numbers in the trial increase, I believe we'd be lucky to reach 276 events in 2011. It's good when people live longer, but a lot of people living longer will stall the completion of the trial unless the company, and the FDA determine to call the trial complete when say a combination of 276 people have died, or are living for over XX months. If XX were 18 months, perhaps the trial would end by mid 2011 as by that time, roughly 300 patients in the trial will have been there 18 months. I believe that some patients in the trial, like Richard Jordan, will eventually be officially labeled Cured, but it won't happen during the trial as such a finding requires at least 5 years cancer free without further treatment as I understand it.
I believe a blind man could see this drug is worthy of approval, however the FDA at times cannot see as much as a blind man.
Gary
